Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo de segurança e eficácia avaliando CTX001 em indivíduos com doença falciforme grave

21 de agosto de 2026 atualizado por: Vertex Pharmaceuticals Incorporated

Um estudo de fase 1/2/3 para avaliar a segurança e a eficácia de uma dose única de células-tronco e progenitoras humanas CD34+ modificadas CRISPR-Cas9 autólogas (CTX001) em indivíduos com doença falciforme grave

Este é um estudo de Fase 1/2/3 de braço único, aberto, multi-local, de dose única em indivíduos com doença falciforme grave (SCD). O estudo avaliará a segurança e a eficácia das células-tronco e progenitoras humanas CD34+ modificadas CRISPR-Cas9 autólogas (hHSPCs) usando CTX001.

Visão geral do estudo

Status

Concluído

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Real)

63

Estágio

  • Fase 2
  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Düsseldorf, Alemanha
        • University Hospital Duesseldorf
      • Regensburg, Alemanha
        • Regensburg University Hospital, Clinic and Polyclinic for Paediatric and Adolescent Medicine, Paediatric Haemotology, Oncology and Stem Cell Transplantation
      • Brussels, Bélgica
        • Hopital Universitaire des Enfants Reine Fabiola (HUDERF)
      • Toronto, Canadá
        • The Hospital for Sick Children
    • California
      • Palo Alto, California, Estados Unidos, 94304
        • Lucile Packard Children's Hospital of Stanford University
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60611
        • Ann & Robert Lurie Children's Hospital of Chicago
      • Chicago, Illinois, Estados Unidos, 60612
        • University of Illinois at Chicago Hospitals and Health Systems
    • New York
      • New York, New York, Estados Unidos, 10032
        • Columbia University Medical Center (21+ years)
      • New York, New York, Estados Unidos, 10032
        • Columbia University Medical Center (≤21 years)
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • Children's Hospital of Philadelphia
    • Tennessee
      • Memphis, Tennessee, Estados Unidos, 38105
        • St. Jude Children's Research Hospital
      • Nashville, Tennessee, Estados Unidos, 37203
        • The Children's Hospital at TriStar Centennial Medical Center/ Sarah Cannon Center for Blood Cancers
    • Texas
      • San Antonio, Texas, Estados Unidos, 78229
        • Methodist Children's Hospital/Texas Transplant Institute
      • Paris, França
        • Hôpital Necker Enfants malades
      • Rome, Itália
        • Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica Ospedale Pediatrico Bambino Gesu - IRCCS
      • London, Reino Unido
        • Imperial College Healthcare NHS Trust, Hammersmith Hospital
      • London, Reino Unido
        • Royal London and St Bartholomew's Hospital, Pathology and Pharmacy Building

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

12 anos a 35 anos (Filho, Adulto)

Aceita Voluntários Saudáveis

Não

Descrição

Principais Critérios de Inclusão:

  • Diagnóstico de doença falciforme grave, conforme definido por:
  • Genótipo documentado da doença falciforme grave
  • História de pelo menos dois eventos de crise vaso-oclusiva grave por ano nos dois anos anteriores à inscrição
  • Elegível para transplante autólogo de células-tronco de acordo com o julgamento dos investigadores

Principais Critérios de Exclusão:

  • Um doador relacionado 10/10 compatível com o antígeno leucocitário humano (HLA) disponível
  • Transplante prévio de células-tronco hematopoiéticas (HSCT)
  • Infecção bacteriana, viral, fúngica ou parasitária clinicamente significativa e ativa

Outros critérios de inclusão/exclusão definidos pelo protocolo podem ser aplicados

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Exa-cel
Exa-cel (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Participants received a single infusion of exa-cel through a central venous catheter on Day 1.
Administered by IV infusion following myeloablative conditioning with busulfan.
Outros nomes:
  • Exagamglogene autotemcel
  • CTX001

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Percentage of Participants Who Have Not Experienced Any Severe Vaso-occlusive Crisis (VOC) for at Least 12 Consecutive Months (VF12) After Exa-cel Infusion
Prazo: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
A VOC is a condition of SCD characterized by vaso-occlusion presenting as recurrent pain episodes. The percentage of participants who remain VOC free after achieving VF12 were data reported in the outcome measure.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of Participants Who Achieve Neutrophil Engraftment
Prazo: Up to 24 months post exa-cel infusion.
Neutrophil engraftment is defined as the first day of 3 consecutive measurements of absolute neutrophil count (ANC)≥500/μL on 3 different days, within 42 days after exa-cel infusion without the use of unmodified CD34+ cells after reaching the nadir, defined as ANC <500/µL.
Up to 24 months post exa-cel infusion.
Time to Neutrophil Engraftment for Participants Who Achieve Neutrophil Engraftment
Prazo: Up to 24 months post exa-cel infusion.
Neutrophil engraftment is defined as the first day of 3 consecutive measurements of absolute neutrophil count (ANC)≥500/μL on 3 different days, without use of the unmodified CD34+ cells after reaching the nadir, defined as ANC<500/μL. Time to neutrophil engraftment was calculated by the neutrophil engraftment date subtract exa-cel infusion date +1.
Up to 24 months post exa-cel infusion.
Time to Platelet Engraftment for Participants Who Achieve Platelet Engraftment
Prazo: From Exa-cel infusion up to 2 years after exa-cel infusion
Platelet engraftment is defined as the first day of 3 consecutive measurements of unsupported (no platelet transfusions for the last 7 days) platelet ≥50,000/μL on 3 different days after Exa-cel infusion. For participants discharged early day 7 after the last platelet transfusion will be the day of platelet engraftment, as long as 3 subsequent and consecutive unsupported measurements on 3 different days are >50,000/μL. For participants who have been discharged prior to platelet engraftment, it is recommended to collect blood every 2 to 3 days to obtain an accurate assessment of platelet engraftment. Time to platelet engraftment was defined as first of 3 consecutive measurements on 3 different days with platelet ≥50 × 109/L without a platelet transfusion for 7 consecutive days.
From Exa-cel infusion up to 2 years after exa-cel infusion
Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Prazo: From receiving exa-cel infusion up to 2 years
From receiving exa-cel infusion up to 2 years
Transplant-related Mortality (TRM) Within 100 Days After Exa-cel Infusion
Prazo: Within 100 days after exa-cel infusion
The transplant-related mortality is defined as death related to Busulfan and/or exa-cel infusion. The number and proportion of TRM participants who have died within 100 days, or with at least 100 days post exa-cel infusion.
Within 100 days after exa-cel infusion
Transplant-related Mortality Within 12 Months Post Exa-cel Infusion
Prazo: Within 12 months post exa-cel infusion
The transplant-related mortality is defined as death related to Busulfan and/or exa-cel infusion. The number and proportion of TRM within 12 months will be summarized for participants who have died within 12 months, or with at least 12 months post exa-cel infusion.
Within 12 months post exa-cel infusion
All-cause Mortality
Prazo: From exa-cel infusion up to 2 years
All-cause mortality from exa-cel infusion up to 2 years
From exa-cel infusion up to 2 years

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Percentage of Participants Free From Inpatient Hospitalization for Severe VOCs Sustained for at Least 12 Months (HF12)
Prazo: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
The HF12 means Free from inpatient hospitalization for severe vaso-occlusive crises (VOCs) and sustained for at least 12 months after exa-cel infusion.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion
Prazo: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
The VF12 defines absence of any severe vaso-occlusive crises (VOCs) for at least 12 consecutive months after exa-cel infusion. Only severe VOCs adjudicated by an outcome measure adjudication committee as meeting the protocol definition of severe VOCs were included in the analysis. Relative reduction from baseline was calculated as 100 % × (Baseline value - post-baseline value) / Baseline value. Annualized rate is calculated by the Total number of events/number of years.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of Participants With at Least 90% Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion
Prazo: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of participants with at least 90% relative reduction from baseline was reported. The percentages were calculated relative to the number of participants who did not achieve VF12.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of Participants With at Least 80% Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion
Prazo: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of participants with at least 80% relative reduction from baseline was reported. The percentages were calculated relative to the number of participants who did not achieve VF12.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of Participants With at Least 75% Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion
Prazo: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of participants with at least 75% relative reduction from baseline was reported. The percentages were calculated relative to the number of participants who did not achieve VF12.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of Participants With at Least 50% Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion
Prazo: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of participants with at least 50% relative reduction from baseline was reported. The percentages were calculated relative to the number of participants who did not achieve VF12.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Duration of Severe VOC Free in Participant Who Have Achieved VF12
Prazo: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
The VF12 means the absence of any severe VOC for at least 12 consecutive months after exa-cel infusion. The evaluation of the severe VOC free duration in participants who achieved VF12 started 60 days after the last RBC transfusion for post transplant support or SCD management.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Relative Reduction From Baseline in Annualized Rate of Inpatient Hospitalizations for Severe VOCs Up to 24 Months After Exa-cel Infusion
Prazo: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion

The HF12 means Free from inpatient hospitalization for severe vaso-occlusive crises (VOCs) and sustained for at least 12 months after exa-cel infusion. Relative reduction from baseline is calculated as 100% × (Baseline value - post-baseline value) / Baseline value. Annualized rate is calculated by the Total number of events/number of years.

Only severe VOCs adjudicated by an outcome measure adjudication committee as meeting the protocol definition of severe VOCs are included in the analysis.

From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Relative Reduction From Baseline in Annualized Duration of Hospitalization for Severe VOCs Who Did Not Achieve HF12 Up to 24 Months After Exa-cel Infusion
Prazo: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion

The HF12 means Free from inpatient hospitalization for severe vaso-occlusive crises (VOCs) and sustained for at least 12 months after exa-cel infusion. Relative reduction from baseline is calculated as 100% × (Baseline value - post-baseline value) / Baseline value. Annualized rate is calculated by the Total number of events/number of years.

Only severe VOCs adjudicated by an outcome measure adjudication committee as meeting the protocol definition of severe VOCs are included in the analysis.

From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of Participants With Sustained Fetal Hemoglobin (HbF) Greater Than or Equal to (≥) 20% for at Least 3 Months
Prazo: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
The HbF evaluation started 60 days after the last RBC transfusion for post transplant support or SCD management. The last RBC transfusion refers to that in the period of the initial RBC transfusions for post transplant support or SCD management.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of Participants With Sustained HbF ≥ 20% for at Least 6 Months
Prazo: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
The HbF evaluation started 60 days after the last RBC transfusion for post transplant support or SCD management. The last RBC transfusion refers to that in the period of the initial RBC transfusions for post transplant support or SCD management.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of Participants With Sustained HbF ≥20% for at Least 12 Months
Prazo: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
The HbF evaluation started 60 days after the last RBC transfusion for post transplant support or SCD management. The last RBC transfusion refers to that in the period of the initial RBC transfusions for post transplant support or SCD management.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Number of Annualized Red Blood Cells (RBC) Units Transfused After Exa-cel Infusion
Prazo: 2 years after exa-cel infusion
The evaluation of the number of annualized RBC units transfused after exa-cel infusion started 12 months after exa-cel infusion.
2 years after exa-cel infusion
Participants With Relative Reduction From Baseline in Number of Annualized Units of Red Blood Cells Transfused
Prazo: 2 years after exa-cel infusion
Relative reduction from baseline = 100% × (Baseline value - post baseline value)/Baseline value. The evaluation of the number of annualized RBC units transfused after exa-cel infusion started 12 months after exa-cel infusion.
2 years after exa-cel infusion
Total Fetal Hemoglobin (HbF) Concentration Over Time
Prazo: 2 years after exa-cel infusion
2 years after exa-cel infusion
Total Hemoglobin (Hb) Concentration Over Time
Prazo: 2 years after exa-cel infusion
2 years after exa-cel infusion
Change From Baseline in Reticulocyte Count Over Time
Prazo: 2 years after exa-cel infusion
2 years after exa-cel infusion
Change From Baseline in Indirect Bilirubin Over Time
Prazo: 2 years after exa-cel infusion
2 years after exa-cel infusion
Percentage of Participants With Detectable Haptoglobin Over Time
Prazo: 2 years after exa-cel infusion
2 years after exa-cel infusion
Percentage of Participants With Lactate Dehydrogenase (LDH) Level <300 Units Per Liter (U/L) Over Time
Prazo: 2 years after exa-cel infusion
2 years after exa-cel infusion
Percentage of Alleles With Intended Genetic Modification Present in Peripheral Blood Leukocytes Over Time
Prazo: 2 years after exa-cel infusion
2 years after exa-cel infusion
Percentage of Alleles With Intended Genetic Modification Present in CD34+ Cells of Bone Marrow Over Time
Prazo: 2 years after exa-cel infusion
2 years after exa-cel infusion
Change in Patient-reported Outcome (PRO) Over Time Assessed Using on a 11-point Numerical Rating Scale [NRS]) for Participants ≥12 and <18 Years of Age
Prazo: 2 years after exa-cel infusion
The 11-point pain numerical rating scale (NRS) is used to measures pain intensity on a 1-dimensional score ranging from 0 (no pain) to 10 (worst possible pain).
2 years after exa-cel infusion
Change in Patient-reported Outcome (PRO) Over Time Assessed Using on a 11-point Numerical Rating Scale [NRS]) for Participants ≥18 and ≤35 Years of Age
Prazo: 2 years after exa-cel infusion
The 11 point pain numerical rating scale (NRS) is used to measures pain intensity on a 1 dimensional score ranging from 0 (no pain) to 10 (worst possible pain).
2 years after exa-cel infusion
Change in PRO Over Time Assessed Using EuroQol Quality of Life Scale (EQ-5D-Y)Visual Analogue Scale (VAS) for Participants ≥12 and <18 Years of Age
Prazo: 2 years after exa-cel infusion
The EQ-5D VAS is a version of the EQ-5D designed for children and adolescents S). The EQ VAS records the subject's self-rated health on a 100-point VAS scale that ranged from 0 (worst imaginable health) to 100 (best imaginable health) points.
2 years after exa-cel infusion
Change in PRO Over Time Assessed Using EuroQol Quality of Life Scale (EQ-5D-5L) for Participants ≥18 and ≤35 Years of Age
Prazo: 2 years after exa-cel infusion
The EQ-5D VAS is a version of the EQ-5D designed for children and adolescents S). The EQ VAS records the subject's self-rated health on a 100-point VAS scale that ranged from 0 (worst imaginable health) to 100 (best imaginable health) points.
2 years after exa-cel infusion
Change in PRO Over Time Assessed Using Functional Assessment of Cancer Therapy-bone Marrow Transplant (FACT-BMT) Score for Participants ≥18 and ≤35 Years of Age
Prazo: 2 years after exa-cel infusion
The Functional Assessment of Cancer Therapy-Bone Marrow Transplant scale (FACT-BMT) is a quality of life instrument that assesses the effects of bone marrow transplantation (BMT) on a patient's physical, social/family, emotional, and functional well-being while taking into consideration BMT-specific concerns. The assessment has different questions, each scored on a Likert scale from 0-4. The overall score is computed by adding scores of the questions and falls in the range 0-148, with higher scores indicating higher levels of overall well-being.
2 years after exa-cel infusion
Change in PRO Over Time Assessed Using Adult Sickle Cell Quality of Life Measurement System (ASCQ-Me) Score on Different Domains for Participants ≥18 and ≤35 Years of Age
Prazo: 2 years after exa-cel infusion
ASCQ-Me is a disease-specific HRQoL questionnaire for adults with sickle cell disease that assesses Emotional Impact, Pain Impact, Social Functioning Impact, Stiffness Impact, Sleep Impact, Pain Episode Frequency, and Pain Episode Severity. Domain scores are reported as T-scores standardized to a reference population where mean = 50, and SD = 10. A change of approximately 5 points (1/2 SD) is considered clinically meaningful. An increase of 5 points indicates improvement for the impact domains, whereas a decrease of 5 points indicates improvement for the Pain Episode Frequency and Pain Episode Severity domains. For impact domain items higher score indicates better HRQoL and lower disease burden. For Pain items lower score indicates a better outcome. Scores are interpreted relative to the reference population mean of 50, taking into account the direction of scoring for each domain.
2 years after exa-cel infusion
Change in PRO Over Time Assessed Using Pediatric Quality of Life Inventory (PedsQL) for Participants Greater Than or Equal to (≥) 12 and Less Than (<) 18 Years of Age
Prazo: 2 years after Exa-cel infusion
PedsQL scores were used to assess quality of life of participants. It is a standardized, generic instrument for measuring health related quality of life (HRQoL) in children and adolescents. It includes different domains (Psychosocial health, physical functioning, emotional functioning, social functioning, and school functioning). When completing the PedsQL questionnaires, respondents were asked to provide a response on a 5-point scale ranging from 0 (never a problem) to 4 (almost always a problem). Responses were then transformed to a 0 to 100 score, with higher scores reflecting better quality of life.
2 years after Exa-cel infusion
Change in PRO Over Time Assessed Using Pediatric Quality of Life Inventory (PedsQL) Sickle Cell Disease Module (SCD) for Participants Greater Than or Equal to (≥) 12 and Less Than (<) 18 Years of Age
Prazo: 2 years after exa-cel infusion
The PedsQL Sickle Cell Disease Module (PedsQL SCD) is a disease-specific module of the PedsQL. The tool measures self-reported health-related quality of life in participants with SCD across 9 domains: pain and hurt, pain impact, pain management (mgmt), worry I, worry II, emotions, treatment, communication I, and communication II. When completing the PedsQL SCD Module questionnaires, respondents were asked to provide a response on a 5-point scale ranging from 0 (never a problem) to 4 (almost always a problem). Responses were then transformed to a 0 to 100 score, with higher scores reflecting better quality of life.
2 years after exa-cel infusion

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

27 de novembro de 2018

Conclusão Primária (Real)

7 de julho de 2025

Conclusão do estudo (Real)

7 de julho de 2025

Datas de inscrição no estudo

Enviado pela primeira vez

9 de novembro de 2018

Enviado pela primeira vez que atendeu aos critérios de CQ

15 de novembro de 2018

Primeira postagem (Real)

19 de novembro de 2018

Atualizações de registro de estudo

Última Atualização Postada (Real)

16 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

21 de agosto de 2026

Última verificação

1 de agosto de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Sim

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever